不用本金就能赚钱的方法

来宝网Logo

热门词:生物显微镜 水质分析仪 微波消解 荧光定量PCR 电化学工作站 生物安全柜

现在位置不用本金就能赚钱的方法>技术资料不用本金就能赚钱的方法>行业动态>公司动态>GSK 2.5亿欧元收购瑞士疫苗平台Okairos AG

GSK 2.5亿欧元收购瑞士疫苗平台Okairos AG

GSK2013年5月31日 11:50 点击:1271

英国葛兰素史克GSK GlaxoSmithKline  意大利Okairos


2013年5月29日 葛兰素史克(GSK)宣布,耗资2.5亿欧元(约合3.25亿美元)现金收购瑞士私人控股疫苗平台技术开发公司—Okairos AG,该公司已开发了一种新颖的疫苗平台技术,该技术预计将在GSK新的预防性疫苗(prophylactic vaccine)和新一类的治疗性疫苗(therapeutic vaccine)开发中发挥重要作用。

不用本金就能赚钱的方法Okairos AGDEJISHUNENGGOUYUGSKXIANYOUDEYIMIAOJISHUJIZHUANYEZHISHIHUBU,JIANGSHIGSKNENGGOUJIXUQIXINYIDAIYIMIAODEKAIFAGONGZUO。

根据协议条款,GSK将收购Okairos AG的全部股权,同时将拥有开发用于呼吸道合胞病毒(RSV)、丙型肝炎病毒(HCV)、疟疾、肺结核、埃博拉病毒、HIV的数个早期资产,来补充GSK现有的疫苗管线。

 

GSK strengthens vaccines business with acquisition of Okairos

不用本金就能赚钱的方法- GSK to further expand its vaccines platform technology expertise through strategic acquisition

Issued: Wednesday 29 May 2013, London UK

不用本金就能赚钱的方法GlaxoSmithKline (GSK) today announced that it has acquired Okairos AG (Okairos), a specialist developer of vaccine platform technologies for €250 million (approximately £215 million/$325 million) in cash.

Swiss-based Okairos, a private company, has developed a novel vaccine platform technology which is expected to play an important role in GSK’s development of new prophylactic vaccines (designed to prevent infection) as well as new classes of therapeutic vaccines (designed to treat infection or disease). Okairos’ technology complements GSK’s existing vaccine technology and expertise and will enable GSK to continue its work developing the next generation of vaccines. The deal also includes a small number of early stage assets.

不用本金就能赚钱的方法The acquisition reinforces GSK’s commitment to investment in innovative science. GSK’s vaccines business sits alongside pharmaceuticals and consumer healthcare as part of a balanced business and product portfolio capable of delivering sustainable sales growth.

Christophe Weber, President, GSK Vaccines said: 不用本金就能赚钱的方法“This is a fantastic opportunity for patients and our research organisation as it is expected to contribute to the development efforts for an exciting new generation of vaccines, building on the excellent science and expertise of both companies.”

Riccardo Cortese, Chief Executive Officer and founder, Okairos, said: "I am extremely pleased with this agreement, which will enable GSK to build on the hard work we have put into developing our vaccines and platforms to the stage that they are at today.  With its considerable resources and know-how, I am confident that GSK is best-placed to maximise this opportunity to potentially transform the vaccines landscape.”

Under the terms of the transaction, GSK will take full ownership of the company and thus assume ownership of early stage assets for diseases such as respiratory syncytial virus (RSV), hepatitis C virus (HCV), malaria, tuberculosis, ebola and HIV, supplementing the company’s existing vaccines pipeline.  GSK and the Okairos management team are committed to an innovative collaboration and will work together over the next few months to develop ways of working that will maintain the autonomy, spirit and agility of this unique small biotech firm which will be strengthened by the support and advantages that GSK can provide.

Okairos was supported by investments from the following life science venture capital firms: BioMedInvest, the Boehringer Ingelheim Venture Fund, LSP, Novartis Venture Funds and Versant Ventures.

GlaxoSmithKline – one of the world’s leading research-based pharmaceutical and healthcare companies – is committed to improving the quality of human life by enabling people to do more, feel better and live longer.  For further information please visit 
 

Okairos - is a non-listed clinical-stage biopharmaceutical company, developing genetic vaccines for major infectious diseases - including malaria, hepatitis C, HIV, respiratory syncytial virus and cancer - using a novel proprietary technology.  The company is also pursuing therapeutic vaccines to treat cancer.  For more information, visit 

(来源: GSK )


全年征稿 / 资讯合作

联系邮箱:kefu@strauss-usa.com不用本金就能赚钱的方法

不用本金就能赚钱的方法 BANQUANYUMIANZESHENGMING

  • 凡本网注明“来源:来宝网”的所有作品,版权均属于来宝网,转载请必须注明来宝网, http://strauss-usa.com,违反者本网将追究相关法律责任。
  • 本网转载并注明自其它来源的作品,目的在于传递更多信息,并不代表本网赞同其观点或证实其内容的真实性,不承担此类作品侵权行为的直接责任及连带责任。其他媒体、网站或个人从本网转载时,必须保留本网注明的作品来源,并自负版权等法律责任。
  • 如涉及作品内容、版权等问题,请在作品发表之日起一周内与本网联系,否则视为放弃相关权利。


湖南快乐十分 湖南快乐十分 福建快3走势图0 福建快3走势图 河南快3走势图 河南快3走势图 广东11选5开奖结果 福建11选5走势图